Ianalumab versus placebo for Sjögren's disease with high symptom burden
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study tests whether a new drug called ianalumab can reduce dry mouth and other symptoms in people with Sjögren's disease—a condition where the immune system attacks moisture-producing glands. Participants will receive either ianalumab or a placebo (inactive injection) over 52 weeks to see if the drug helps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older
- You have been diagnosed with Sjögren's disease confirmed by specific blood tests (anti-Ro/SSA antibodies) and clinical criteria
- You have moderate to high symptoms of dry mouth and overall symptom burden (measured over 14 days)
- You have some biological signs of disease activity in blood work (abnormalities linked to Sjögren's, not other conditions)
- You still produce some saliva when your mouth is stimulated (more than 0.3 mL per minute)
- You have not received certain immune-suppressing treatments recently (B-cell-depleting drugs, belimumab, rituximab, or similar medications within specific timeframes)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ianalumab for people with diffuse cutaneous systemic sclerosis (a type of scleroderma affecting the skin and internal organs). It aims to see if the drug can help control the disease activity and reduce skin thickening.
This trial tests an experimental drug, IMVT-1402, in adults with primary Sjogren's disease who have moderate to severe symptoms. The goal is to see if it can reduce disease activity safely.
This study tests an experimental drug called DDY391 for people with Sjögren's disease. The goal is to see if it can reduce symptoms and improve quality of life, and to check for side effects.
This trial studies whether iguratimod improves symptoms in people with primary Sjögren’s syndrome, and checks how safe it is. It focuses on people with confirmed disease markers (anti-SSA/Ro-60) and ongoing dry eyes and dry mouth.
This study tests a new drug called CM336 for people with primary Sjögren's syndrome (an autoimmune disease affecting salivary and tear glands). The drug is designed to help reduce disease activity in patients who haven't responded well to previous treatments.
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
Hear when a new Sjögren´s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.